Search

Displaying results 5041 - 5050 of 10000 in total
  1. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate … AVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis.

  2. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].

  3. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.

  4. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. … [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).

  5. Drug

    Bilastine

    go.drugbank.com/drugs/DB11591
    Approved

    Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

  6. Drug

    Heptabarbital

    go.drugbank.com/drugs/DB01354
    Experimental

    Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.

  7. Drug

    GTI-2501

    go.drugbank.com/drugs/DB05406
    Experimental

    GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. … The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.

  8. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). … It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors

  9. Drug

    Ciclopirox

    go.drugbank.com/drugs/DB01188
    ApprovedInvestigational

    In particular, the agent is especially effective in treating Tinea versicolor. … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses.

  10. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.